Protalix Biotherapeutics gains momentum in the rare disease space: analysts
Portfolio Pulse from
Protalix Biotherapeutics Inc (NYSE-A:PLX) has received positive assessments from analysts, with HC Wainwright and Zacks Small Cap Research raising their price targets due to strong revenue growth from its Fabry disease treatment, Elfabrio, and a promising pipeline.
February 04, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protalix Biotherapeutics has received bullish analyst ratings due to strong revenue growth from its Fabry disease treatment, Elfabrio, and a promising pipeline. HC Wainwright raised its price target to $15, while Zacks maintained a $14 valuation.
The positive analyst ratings and increased price targets are likely to boost investor confidence in Protalix Biotherapeutics. The strong revenue growth from Elfabrio and a robust pipeline suggest potential for sustainable profitability, which is a positive indicator for the stock's short-term performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100